What MoonLake Immunotherapeutics does.

We are a clinical stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases. We are currently a single asset company focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody, that we exclusively licensed from MHKDG and that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.

SLK is a proprietary Nanobody that was discovered by Ablynx N.V., Belgium, a Sanofi company (“Ablynx”), and previously studied by MHKDG and Avillion LLP (“Avillion”) under a 2017 co-development agreement. The terms “Nanobody” and “Nanobodies” used herewith are registered trademarks of Ablynx. Nanobodies are able to bind selectively to a specific antigen with high affinity. Nanobodies have a fraction of the molecular weight compared to traditional antibodies. They offer a number of potential advantages over traditional monoclonal antibodies, including the potential to create multivalent molecules with enhanced ability to penetrate inflamed tissue, especially when containing an additional albumin binding domain such as SLK, an easier manufacturing process and a higher thermostability.

Revenue and profit, by fiscal year.

More on MLTX.

• MoonLake Immunotherapeutics summary
• MoonLake Immunotherapeutics financial statements
• MoonLake Immunotherapeutics key metrics
• MoonLake Immunotherapeutics health scores and style box
• MoonLake Immunotherapeutics earnings
• MoonLake Immunotherapeutics dividends
• MoonLake Immunotherapeutics valuation
• MoonLake Immunotherapeutics ownership and insiders
• MoonLake Immunotherapeutics peers

Figures from MoonLake Immunotherapeutics's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.